Navigation Links
Study shows interruption of antiretroviral therapy increases risk of disease and death

rofessor of clinical Medicine and Epidemiology, "Interruption of antiretroviral therapy has been generally advocated as a potential treatment strategy to enhance the quality of life, limit side effects, and allow for the emergence of the predominant wild-type virus in patients infected with multidrug-resistant HIV. However, our data clearly demonstrate that continuous use of anti-retroviral therapy is superior to its episodic use."

In the SMART Study, researchers from more than 30 countries around the world randomly assigned 5,472 participants infected with HIV with a CD4+ cell count of more than 350 per cubic millimeter to the continuous use of antiretroviral therapy or to the episodic use of antiretroviral therapy. The participants?,720 in the episodic therapy group and 2,752 in the continuous therapy group—were followed for an average of 16 months. Episodic therapy involved only using antiretroviral therapy when the CD4+ count decreased to less than 250 per cubic millimeter and then stopping therapy when the CD4+ count increased to more than 350 per cubic millimeter. The primary end point was the development of an opportunistic disease or death from any cause. An important secondary end point was major cardiovascular, renal, or hepatic disease.

There were 120 participants in the episodic therapy group and 47 in the continuous therapy group who had an opportunistic disease or died from any cause. Analysis of study data showed that those on episodic therapy had more than twice the risk of developing these endpoints compared to those in the continuous therapy group. In addition, participants in the episodic group experienced significantly more cardiac, renal, and hepatic complications. Observes Dr. El Sadr, "The latter finding is surprising considering that cardiac complications have been associated in other studies with such events and liver and kidney complications have been linked to such treatment."

According to Dr. El-Sadr, "Our find
'"/>

Source:Columbia University's Mailman School of Public Health


Page: 1 2 3

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
3. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
4. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
5. Study Links Ebola Outbreaks To Animal Carcasses
6. Breakthrough Microarray-based Technology for the Study of Cancer
7. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
8. Study finds more than one-third of human genome regulated by RNA
9. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
10. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
11. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
Post Your Comments:
(Date:3/24/2015)... NexID Biometrics LLC, whose spoof-mitigation technology boosts protection ... beginning of shipments of version 2.0 of its industry ... in Potsdam, N.Y. , is making ... here today at the Walter E. Washington Convention Center. ... boosts the accuracy rate range to 96.5 to 99.5 ...
(Date:3/23/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet, ... March 30 th . The new ... York markets. Gino Pereira ... new ad campaign following the recent initial shipment of Wocket ...
(Date:3/19/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, announces its biometric payment technology, the Wocket® smart ... week on Washington DC,s Fox 5 ... "The Next Great Thing", host Laura Evans calls ... ,a really big breakthrough in mobile payment.,  ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... Scientists from the EPFL and the University of Geneva ... our members in which, surprisingly, genes play only a secondary ... 23rd of November, shows the mechanism is found in a ... This long string has seven enhancers which, when combined with ...
... Biomolecular Labeling Laboratory, the National Institute of Standards and ... of facilities in the world that specializes in tagging ... to analyze. The new NIST lab is available to ... want to take advantage of the NIST Center for ...
... idea that one can create a field of science out ... is a bold concept. But for the emerging field ... making sense of potentially divergent theory, practice and policy, the ... the Proceedings of the National Academy of Sciences , ...
Cached Biology News:Finger (mal)formation reveals surprise function of desert DNA 2Tags? We're it. NIST opens new 'biolabeling' research facility 2Is sustainability science really a science? 2
(Date:4/21/2015)... Invetech , a global leader ... contract manufacturing, and  NanoCellect Biomedical, a company ... sorting technology for life science researchers, today announced ... platform. Headquartered in San ... microchip-based cell sorting technology. NanoCellect,s flow cytometry platform ...
(Date:4/21/2015)... 2015  scPharmaceuticals, Inc., a privately held ... subcutaneous delivery, announced today that it has ... proprietary drug product, Furosemide Injection Solution, for ... heart failure. Concurrently with its ... patch pump.  The patch pump is designed ...
(Date:4/21/2015)... 2015 Leading-edge research into ... will be presented at the 2nd International ... and clinicians from academia, industry and government ... Invibio Biomaterial Solutions. The world-leading solutions provider ... manufacturing and R&D for medical-device manufacturers, holds ...
(Date:4/20/2015)... VANCOUVER, British Columbia and ...   DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ... on developing and commercializing proven cancer therapies in ... data at the 106th Annual Meeting of ... Annual Meeting on the potential for its lead ...
Breaking Biology Technology:NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 2NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 3scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 2scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 32nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 22nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5
... a tenured animal sciences professor at the University of Wisconsin-Madison, ... only to sit on the shelves. , ,Hed been working ... being promoted by any of the businesses to which it ... ,This technology has just been sitting there since about 1994 ...
... a new way to see vital vehicle and patient information ... the traditional series of gauges and lights with a display ... streamline controls while providing drivers with more information. , ,Theres ... the Schmitz Company , public relations for HED. What ...
... see that cloud, thats almost in shape like a camel? ... ,Hamlet: Methinks it is like a weasel. ,Polonius: It is ... Very like a whale. , Hamlet , by Edward ... ,Occasionally stumbling across truth but mostly skilled in sycophancy, Polonius ...
Cached Biology Technology:Scientist takes back patents and develops product others ignored 2Scientist takes back patents and develops product others ignored 3Hartford firm brings video to the dashboard 2Hartford firm brings video to the dashboard 3Follow these three rules when choosing tech consultants 2Follow these three rules when choosing tech consultants 3Follow these three rules when choosing tech consultants 4